Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKesson
Julphar
Cantor Fitzgerald
Queensland Health
Express Scripts
Chinese Patent Office
Baxter
Moodys

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,583,174

« Back to Dashboard

Which drugs does patent 6,583,174 protect, and when does it expire?

Patent 6,583,174 protects AMITIZA and is included in one NDA.

This patent has thirty-nine patent family members in twenty-four countries.
Summary for Patent: 6,583,174
Title: Composition and method for stabilizing the same
Abstract:Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Habe; Tsuyoshi (Sasayama, JP)
Assignee: Sucampo, A.G. (Zurich, CH)
Application Number:09/688,351
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 6,583,174

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,583,174

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,417,067 Composition and method for stabilizing the same ➤ Sign Up
8,097,649 Composition and method for stabilizing the same ➤ Sign Up
8,088,934 Composition and method for stabilizing the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Dow
Baxter
Chinese Patent Office
Daiichi Sankyo
Healthtrust
Farmers Insurance
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.